FDA finalizes 3 biosimilars guidances
This article was originally published in Scrip
Executive Summary
The FDA can knock three biosimilars guidances off its to-do list after finalizing the documents and giving industry more certainty on US regulators' thinking about what's needed to submit so-called 351(k) applications to the agency and gain approval.